Compare DHY & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DHY | ZVRA |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.4M | 689.4M |
| IPO Year | 1998 | 2015 |
| Metric | DHY | ZVRA |
|---|---|---|
| Price | $16.23 | $10.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 724.8K | ★ 849.5K |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $43.97 |
| Revenue Next Year | N/A | $15.93 |
| P/E Ratio | ★ N/A | $15.30 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $1.61 | $8.01 |
| 52 Week High | $16.67 | $15.04 |
| Indicator | DHY | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 97.12 | 39.50 |
| Support Level | $1.77 | $10.07 |
| Resistance Level | $16.67 | $11.07 |
| Average True Range (ATR) | 0.23 | 0.48 |
| MACD | 0.72 | 0.01 |
| Stochastic Oscillator | 97.01 | 34.14 |
Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.